Detalhe da pesquisa
1.
Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraine.
Headache
; 2024 May 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38800847
2.
Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study.
Headache
; 63(9): 1251-1258, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37740562
3.
The Gut-brain Connection and Episodic Migraine: an Update.
Curr Pain Headache Rep
; 27(11): 765-774, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37792173
4.
Trial of Galcanezumab in Prevention of Episodic Cluster Headache.
N Engl J Med
; 381(2): 132-141, 2019 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31291515
5.
Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure.
J Headache Pain
; 23(1): 148, 2022 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36414952
6.
Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine.
Cephalalgia
; 41(3): 340-352, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33143451
7.
Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
BMC Neurol
; 21(1): 175, 2021 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33892641
8.
A link between gastrointestinal disorders and migraine: Insights into the gut-brain connection.
Headache
; 61(4): 576-589, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33793965
9.
STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD® ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients.
Headache
; 61(8): 1214-1226, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34363701
10.
Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine.
J Headache Pain
; 22(1): 6, 2021 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33549036
11.
Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache.
Cephalalgia
; 40(9): 903-912, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32580575
12.
Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment.
Cephalalgia
; 40(9): 935-948, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32050782
13.
Systematic Review: Acupuncture vs Standard Pharmacological Therapy for Migraine Prevention.
Headache
; 60(2): 309-317, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31872864
14.
The Role of Diet and Nutrition in Migraine Triggers and Treatment: A Systematic Literature Review.
Headache
; 60(7): 1300-1316, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32449944
15.
Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1, EVOLVE-2, and REGAIN Studies.
Headache
; 60(1): 110-123, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31721185
16.
Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies.
Headache
; 60(2): 348-359, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31710104
17.
Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.
Brain
; 142(7): 1894-1904, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31132795
18.
Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis.
J Neurol Neurosurg Psychiatry
; 90(8): 939-944, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31004075
19.
Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure.
Cephalalgia
; 39(8): 931-944, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31104507
20.
CGRP and the Trigeminal System in Migraine.
Headache
; 59(5): 659-681, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30982963